NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,655.52 mln
Float51.00 mln
Earnings Date08/17/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
142
Transformational upside
Relative Strength
19
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-27.06
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Oruka Therapeutics is a clinical-stage medicine company based in Menlo Park, California, working to develop new antibody-based treatments for psoriasis and related inflammatory conditions. Its two lead treatments, ORKA-001 and ORKA-002, are currently in mid-stage clinical trials targeting different proteins involved in driving inflammation. The company is also exploring additional treatment approaches, including a combined therapy that uses both lead drugs in sequence.
